The cardiac Na+ channel SCN5A (Nav1.5) and the inward depolarizing Na+ current (INa) play a critical role in regulating the action potential of myocytes in the atrium, ventricle, and specialized conduction system. Mutations in SCN5A are associated with several arrhythmia phenotypes including long QT syndrome, Brugada syndrome, and dilated cardiomyopathy. Brugada Syndrome has also been linked to a mutation in the gene for the glycerol-3-phosphate dehydrogenase-like (GPD1-L) protein, which is dependent on the balance of cellular NADH and NAD+, and thus the energetic state of the cell. SIRT1 is a mammalian protein lysine deacetylase which belongs to the SIRTUIN family of NAD+-dependent deacetylases. SIRT1 targets many proteins for lysine deacetylation in response to changes in the energetic state of the cell. Whether SIRT1 targets cardiac ion channels, and SCN5A in particular, and thus plays a role in regulating cardiac excitability is not known. Moreover, potential interactions between GPD1-L, the metabolic state of ventricular myocytes, and SIRT1 activity are completely unexplored. This revised application is based on very novel preliminary data that SIRT1 interacts with Nav1.5 and GPD1-L to regulate INa. It hypothesizes that dynamic lysine acetylation and deacetylation is a previously undescribed post-translational modification of SCN5A that regulates INa, that SIRT1-dependent deacetylation of Nav1.5 increases INa, that GPD1-L mutations alter INa through changes in SIRT-mediated deacetylation of Nav1.5, and that changes in SIRT1 can modify arrhythmic risk. It will critically test these hypotheses using HEK 293 cells, rat neonatal cardiac myocytes, iPS-derived cardiac myocytes and transgenic mice. Deacetylation-mediated activation of Nav1.5 by SIRT1, and its modulation by GPD1-L, will identify an entirely new mechanism for regulation of cardiac INa. In doing so, it will open the door for pharmacologic SIRT1 activators as potential therapeutic agents in patients at risk for cardiac arrhythmias dues to inherited and acquired disturbances in cardiac INa.

Public Health Relevance

Disturbances in cardiac ion currents predispose to cardiac arrhythmias and sudden cardiac death. This application will ask if the longevity protein SIRTUIN1 regulates cardiac excitability by affecting cardiac ion channels.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL115955-01A1
Application #
8531474
Study Section
Electrical Signaling, Ion Transport, and Arrhythmias Study Section (ESTA)
Program Officer
Krull, Holly
Project Start
2013-06-15
Project End
2017-05-31
Budget Start
2013-06-15
Budget End
2014-05-31
Support Year
1
Fiscal Year
2013
Total Cost
$611,661
Indirect Cost
$118,476
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Zhang, Xiaoming; Yoon, Jin-Young; Morley, Michael et al. (2018) A common variant alters SCN5A-miR-24 interaction and associates with heart failure mortality. J Clin Invest 128:1154-1163
London, Barry; Greiner, Alexander M; Mehdi, Haider et al. (2018) IDENTIFYING NEW SUDDEN DEATH GENES. Trans Am Clin Climatol Assoc 129:183-184
Matasic, Daniel S; Brenner, Charles; London, Barry (2018) Emerging potential benefits of modulating NAD+ metabolism in cardiovascular disease. Am J Physiol Heart Circ Physiol 314:H839-H852
London, Barry (2017) Defining the Complexity of the Junctional Membrane Complex. Circ Res 120:11-12
Yoon, Jin-Young; Vikram, Ajit; London, Barry et al. (2017) Reversible lysine acetylation: Another layer of post-translational regulation of the cardiac sodium channel. Channels (Austin) 11:360-361
Vikram, Ajit; Lewarchik, Christopher M; Yoon, Jin-Young et al. (2017) Sirtuin 1 regulates cardiac electrical activity by deacetylating the cardiac sodium channel. Nat Med 23:361-367
London, Barry (2017) Immune Modulation of Cardiac Arrhythmias. Circ Res 121:11-12
Shao, Di; Han, Jingyan; Hou, Xiuyun et al. (2017) Glutaredoxin-1 Deficiency Causes Fatty Liver and Dyslipidemia by Inhibiting Sirtuin-1. Antioxid Redox Signal 27:313-327
London, Barry (2017) United We Stand; Divided We Fibrillate? Circ Res 121:1302-1303